Intrapleural fibrinolytics for pleural infection: Optimizing dosing for future trials [4]

Mayo Clinic Proceedings

Volumn 82, Issue 8, 2007, Pages 1016-

  Heppler, J Scott ^a  

^a Kittitas Valley Community Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; PENICILLIN G; STREPTOKINASE; UROKINASE;

DOSE CALCULATION; DRUG HALF LIFE; DRUG INDICATION; FIBRINOLYTIC THERAPY; HUMAN; LETTER; PLEURISY;

EID: 34547631284     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.8.1016     Document Type: Letter

References (6)

1. Levinson GM, Pennington DW. Intrapleural fibrinolytics combined with image-guided chest tube drainage for pleural infection. Mayo Clin Proc. 2007;82:407-413.
2. Maskell NA, Davies CWH, Nunn AJ, et al, First Multicenter Intrapleural Sepsis Trial (MIST1) Group. U.K. controlled trial of intrapleural streptokinase for pleural infection [published correction appears in N Engl J Med. 2005;352:2146]. N Engl J Med. 2005;352:865-874.
3. Tanswell P, Tebbe U, Neuhaus KL, Glasle-Schwarz L, Wojick J, Seifried E. Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarction. J Am Coll Cardiol. 1992;19:1071-1075.
4. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur Respir J. 1997;10:1150-1156.
5. Ferrer J, Montes JF, Villarino MA, Light RW, Garcia-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis. Chest. 2002;122:1018-1027.
6. MIST2: Multi-centre Intra-pleural Sepsis Trial. Available at: www.ctu.mrc.ac.uk/studies/mist2.asp. Accessed July 17, 2007.